{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:13Z","timestamp":1788279973290,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sun Pharma Laboratories Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40801-025-00497-8","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:09:03Z","timestamp":1750342143000},"page":"411-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Burden of Partial Response to Standard Doses of Proton Pump Inhibitors in Patients with Clinically Diagnosed Gastroesophageal Reflux Disease: A Real-World Evidence Study in India"],"prefix":"10.1007","volume":"12","author":[{"given":"Yogesh","family":"Garje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soujanya","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-6134","authenticated-orcid":false,"given":"Ashwini","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Khandhedia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Markandeywar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhna","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"1","key":"497_CR1","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","volume":"10","author":"JS Nirwan","year":"2020","unstructured":"Nirwan JS, Hasan SS, Babar ZU, Conway BR, Ghori MU. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis. Sci Rep. 2020;10(1):5814. https:\/\/doi.org\/10.1038\/s41598-020-62795-1.","journal-title":"Sci Rep"},{"issue":"2","key":"497_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12664-020-01104-0","volume":"40","author":"SKAGU Rai","year":"2021","unstructured":"Rai SKAGU. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: a meta-analysis and meta-regression study. Ind J Gastroenterol. 2021;40(2):209\u201319.","journal-title":"Ind J Gastroenterol"},{"issue":"6","key":"497_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MCG.0000000000000854","volume":"51","author":"R Hunt","year":"2017","unstructured":"Hunt R, Armstrong D, Katelaris P, et al. World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017;51(6):467\u201378. https:\/\/doi.org\/10.1097\/MCG.0000000000000854.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"497_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5056\/jnm.2014.20.1.64","volume":"20","author":"JC Lopez-Alvarenga","year":"2014","unstructured":"Lopez-Alvarenga JC, Orr W, Vargas-Romero JA, et al. Relief of night-time symptoms associated with gastroesophageal reflux disease following 4 weeks of treatment with pantoprazole magnesium: the Mexican Gastroesophageal Reflux Disease Working Group. J Neurogastroenterol Motil. 2014;20(1):64\u201373. https:\/\/doi.org\/10.5056\/jnm.2014.20.1.64.","journal-title":"J Neurogastroenterol Motil."},{"issue":"8","key":"497_CR5","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus G. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900\u201320. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00630.x. (quiz 1943).","journal-title":"Am J Gastroenterol"},{"key":"497_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1186\/s12913-024-11781-8","volume":"24","author":"P Maresova","year":"2024","unstructured":"Maresova P, Rezny L, Hruska J, Klimova B, Swanstrom LL, Kuca K. Diagnosis and treatment of patients with gastroesophageal reflux disease\u2014a systematic review of cost-effectiveness and economic burden. BMC Health Serv Res. 2024;24:1351. https:\/\/doi.org\/10.1186\/s12913-024-11781-8.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"497_CR7","first-page":"1311","volume":"68","author":"JJ Heidelbaugh","year":"2003","unstructured":"Heidelbaugh JJ, Nostrant TT, Kim C, Van Harrison R. Management of gastroesophageal reflux disease. Am Fam Physician. 2003;68(7):1311\u20138.","journal-title":"Am Fam Physician"},{"issue":"1","key":"497_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356. https:\/\/doi.org\/10.14309\/ajg.0000000000001538.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"497_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","volume":"19","author":"JM Shin","year":"2013","unstructured":"Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25\u201335. https:\/\/doi.org\/10.5056\/jnm.2013.19.1.25.","journal-title":"J Neurogastroenterol Motil"},{"issue":"2","key":"497_CR10","first-page":"273","volume":"66","author":"BT Vanderhoff","year":"2002","unstructured":"Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273\u201380.","journal-title":"Am Fam Physician"},{"issue":"1","key":"497_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/s1086-5802(16)31036-1","volume":"40","author":"LS Welage","year":"2000","unstructured":"Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40(1):52\u201362. https:\/\/doi.org\/10.1016\/s1086-5802(16)31036-1. (quiz 121\u2013123).","journal-title":"J Am Pharm Assoc (Wash)"},{"issue":"1","key":"497_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases\u2014a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. https:\/\/doi.org\/10.1186\/s12916-016-0718-z.","journal-title":"BMC Med"},{"issue":"7","key":"497_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/apt.12007","volume":"36","author":"P Bytzer","year":"2012","unstructured":"Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis\u2014a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36(7):635\u201343. https:\/\/doi.org\/10.1111\/apt.12007.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"497_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bpg.2013.06.005","volume":"27","author":"PJ Kahrilas","year":"2013","unstructured":"Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):401\u201314. https:\/\/doi.org\/10.1016\/j.bpg.2013.06.005.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"497_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/POR.S36704","volume":"3","author":"NO Stalhammar","year":"2012","unstructured":"Stalhammar NO, Spiegel BM, Granstedt Lofman H, et al. Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA. Pragmat Obs Res. 2012;3:57\u201367. https:\/\/doi.org\/10.2147\/POR.S36704.","journal-title":"Pragmat Obs Res."},{"key":"497_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-230X-13-39","volume":"13","author":"S Bruley des Varannes","year":"2013","unstructured":"Bruley des Varannes S, Lofman HG, Karlsson M, et al. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. BMC Gastroenterol. 2013;13:39. https:\/\/doi.org\/10.1186\/1471-230X-13-39.","journal-title":"BMC Gastroenterol"},{"key":"497_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12664-019-00979-y","volume":"38","author":"SJ Bhatia","year":"2019","unstructured":"Bhatia SJ, Makharia GK, Abraham P, et al. Indian consensus on gastroesophageal reflux disease in adults: a position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38:411\u201340.","journal-title":"Indian J Gastroenterol"},{"issue":"10","key":"497_CR18","first-page":"69","volume":"68","author":"S Bhatia","year":"2020","unstructured":"Bhatia S, Pareek KK, Kumar A, et al. API-ISG consensus guidelines for management of gastrooesophageal reflux disease. J Assoc Physicians India. 2020;68(10):69\u201380.","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"497_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12664-018-00931-6","volume":"38","author":"SD Chowdhury","year":"2019","unstructured":"Chowdhury SD, George G, Ramakrishna K, et al. Prevalence and factors associated with gastroesophageal reflux disease in southern India: a community-based study. Indian J Gastroenterol. 2019;38(1):77\u201382. https:\/\/doi.org\/10.1007\/s12664-018-00931-6.","journal-title":"Indian J Gastroenterol"},{"issue":"2","key":"497_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12988","volume":"8","author":"S Lakhtakia","year":"2024","unstructured":"Lakhtakia S, Singh AP, Singla N, Memon SF, Reddy DN. Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: a prospective, open-label, single-arm pilot study. JGH Open. 2024;8(2): e12988. https:\/\/doi.org\/10.1002\/jgh3.12988.","journal-title":"JGH Open"},{"key":"497_CR21","doi-asserted-by":"publisher","first-page":"3926051","DOI":"10.1155\/2019\/3926051","volume":"2019","author":"F Sierra-Arango","year":"2019","unstructured":"Sierra-Arango F, Castano DM, Forero JD, et al. A randomized placebo-controlled N-of-1 trial: the effect of proton pump inhibitor in the management of gastroesophageal reflux disease. Can J Gastroenterol Hepatol. 2019;2019:3926051. https:\/\/doi.org\/10.1155\/2019\/3926051.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"497_CR22","unstructured":"Mathur DR. National ethical guidelines for biomedical and health research involving human participants. Indian Council of Medical Research; 2017:187."},{"issue":"12","key":"497_CR23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.12998\/wjcc.v7.i12.1421","volume":"7","author":"R Gorczyca","year":"2019","unstructured":"Gorczyca R, Pardak P, Pekala A, Filip R. Impact of gastroesophageal reflux disease on the quality of life of Polish patients. World J Clin Cases. 2019;7(12):1421\u20139. https:\/\/doi.org\/10.12998\/wjcc.v7.i12.1421.","journal-title":"World J Clin Cases"},{"issue":"4","key":"497_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K Iwakiri","year":"2022","unstructured":"Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267\u201385. https:\/\/doi.org\/10.1007\/s00535-022-01861-z.","journal-title":"J Gastroenterol"},{"issue":"4","key":"497_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000089957","volume":"72","author":"WC Orr","year":"2005","unstructured":"Orr WC. Therapeutic options in the treatment of nighttime gastroesophageal reflux. Digestion. 2005;72(4):229\u201338. https:\/\/doi.org\/10.1159\/000089957.","journal-title":"Digestion"},{"key":"497_CR26","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2020\/45123.14136","author":"AGA Goyal","year":"2020","unstructured":"Goyal AGA. Prescribing pattern of proton pump inhibitors (PPI) and histamine blockers in a tertiary care hospital. J Clin Diagn Res. 2020. https:\/\/doi.org\/10.7860\/JCDR\/2020\/45123.14136.","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"497_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.31254\/jsir.2016.5201","volume":"5","author":"KK Jha","year":"2016","unstructured":"Jha KK, Divya P, Swetha V, Reddy V, Km B, Doddayya H. Prescribing pattern of acid suppressant drugs in current clinical practice. J Sci Innov Res. 2016;5(2):32\u20135. https:\/\/doi.org\/10.31254\/jsir.2016.5201.","journal-title":"J Sci Innov Res"},{"issue":"33","key":"497_CR28","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3748\/wjg.v13.i33.4467","volume":"13","author":"A Pilotto","year":"2007","unstructured":"Pilotto A, Franceschi M, Leandro G, Scarcelli C, D\u2019Ambrosio LP, Paris F, Annese V, Seripa D, Andriulli A, Di Mario F. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007;13(33):4467\u201372.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"497_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.9790\/0853-1911021620","volume":"19","author":"A Kujur","year":"2020","unstructured":"Kujur A, Ekka N. A study on the prescribing pattern of proton pump inhibitors in the general surgery wards of premier medical institute in Eastern India. IOSR J Dent Med Sci (IOSR-JDMS). 2020;19(11):16\u201320. https:\/\/doi.org\/10.9790\/0853-1911021620.","journal-title":"IOSR J Dent Med Sci (IOSR-JDMS)"},{"issue":"2","key":"497_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0018578719873876","volume":"56","author":"M Zabiuddin Ahad","year":"2021","unstructured":"Zabiuddin Ahad M, Lavu A, Ansari M, Raviraj V, Vilakkathala R. A cross-sectional study on single-day use of proton pump inhibitors in tertiary care hospitals of South India. Hosp Pharm. 2021;56(2):109\u201315. https:\/\/doi.org\/10.1177\/0018578719873876.","journal-title":"Hosp Pharm"},{"key":"497_CR31","doi-asserted-by":"publisher","DOI":"10.1108\/JHR-09-2020-0420","author":"B Basyal","year":"2021","unstructured":"Basyal B, Marasine NR, Sankhi S, Lamichhane R, Uprety BN. Prescribing pattern of proton pump inhibitors among patients visiting the outpatient general medicine clinic in a tertiary care teaching hospital in Nepal. J Health Res. 2021. https:\/\/doi.org\/10.1108\/JHR-09-2020-0420.","journal-title":"J Health Res"},{"issue":"5","key":"497_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1365-2125.2006.02687.x","volume":"62","author":"G Trifir\u00f2","year":"2006","unstructured":"Trifir\u00f2 G, Corrao S, Alacqua M, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol. 2006;62(5):582\u201390. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02687.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"497_CR33","first-page":"242","volume":"6","author":"HS Pathak","year":"2019","unstructured":"Pathak HS, Banik K, Bhattacharya R, Kayal R, Lahiri A. Recent trends of GI symptoms in diabetic population in Eastern India: an original article. Int J Res Rev. 2019;6(12):242\u201350.","journal-title":"Int J Res Rev"},{"issue":"27","key":"497_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004089","volume":"95","author":"CH Chen","year":"2016","unstructured":"Chen CH, Lin CL, Kao CH. Association between gastroesophageal reflux disease and coronary heart disease: a nationwide population-based analysis. Medicine (Baltimore). 2016;95(27): e4089. https:\/\/doi.org\/10.1097\/MD.0000000000004089.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"497_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3748\/wjg.14.709","volume":"14","author":"X Wang","year":"2008","unstructured":"Wang X. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol. 2008;14(5):709. https:\/\/doi.org\/10.3748\/wjg.14.709.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"497_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.0953-0673.1996.00397.x","volume":"10","author":"CJ van Rensburg","year":"1996","unstructured":"van Rensburg CJ, Honiball PJ, Grundling HD, et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther. 1996;10(3):397\u2013401. https:\/\/doi.org\/10.1111\/j.0953-0673.1996.00397.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"497_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","volume":"29","author":"H Blume","year":"2006","unstructured":"Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769\u201384. https:\/\/doi.org\/10.2165\/00002018-200629090-00002.","journal-title":"Drug Saf"},{"issue":"5","key":"497_CR38","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1053\/gast.2002.36593","volume":"123","author":"JM Shin","year":"2002","unstructured":"Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002;123(5):1588\u201397. https:\/\/doi.org\/10.1053\/gast.2002.36593.","journal-title":"Gastroenterology"},{"issue":"2","key":"497_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00018-007-7249-x","volume":"65","author":"JM Shin","year":"2008","unstructured":"Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65(2):264\u201381. https:\/\/doi.org\/10.1007\/s00018-007-7249-x.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"497_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12664-019-00979-y","volume":"38","author":"SJ Bhatia","year":"2019","unstructured":"Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, Ghoshal UC, et al. Indian consensus on gastroesophageal reflux disease in adults: a position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38(5):411\u201340. https:\/\/doi.org\/10.1007\/s12664-019-00979-y.","journal-title":"Indian J Gastroenterol"},{"issue":"10","key":"497_CR41","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/MCG.0000000000001518","volume":"55","author":"CW Howden","year":"2021","unstructured":"Howden CW, Manuel M, Taylor D, Jariwala-Parikh K, Tkacz J. Estimate of refractory reflux disease in the United States: economic burden and associated clinical characteristics. J Clin Gastroenterol. 2021;55(10):842\u201350. https:\/\/doi.org\/10.1097\/MCG.0000000000001518.","journal-title":"J Clin Gastroenterol"},{"key":"497_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-230X-13-39","volume":"13","author":"SB Varannes","year":"2013","unstructured":"Varannes SB, L\u00f6fman HG, Karlsson M, Wahlqvist P, Ruth M, Furstnau ML, Despi\u00e9gel N, St\u00e5lhammar NO. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. BMC Gastroenterol. 2013;13:39. https:\/\/doi.org\/10.1186\/1471-230X-13-39.","journal-title":"BMC Gastroenterol"},{"key":"497_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/POR.S36704","volume":"3","author":"NO Stalhammar","year":"2012","unstructured":"Stalhammar NO, Spiegel BM, Lofman HG, Karlsson M, Wahlqvist P, Naesdal J, Nelson MT, Despiegel N. Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA. Pragmat Obs Res. 2012;3:57\u201367. https:\/\/doi.org\/10.2147\/POR.S36704.","journal-title":"Pragmat Obs Res"},{"issue":"5","key":"497_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197400","volume":"13","author":"J Hughes","year":"2018","unstructured":"Hughes J, Chiu YY, Kalra PA, Green D. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease. PLoS ONE. 2018;13(5): e0197400. https:\/\/doi.org\/10.1371\/journal.pone.0197400.","journal-title":"PLoS ONE"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00497-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00497-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00497-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:35:54Z","timestamp":1757190954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00497-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00497-8","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"7 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Sun Pharma Laboratories Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Yogesh Garje is an ex-employee of Sun Pharmaceutical Industries Ltd. Dr. Neeraj Markandeywar, Dr. Chintan Khandhedia, Shruti Dharmadhikari, Dr Ashwini Satpathy, and Dr. Suyog Mehta are employees of Sun Pharma Laboratories Ltd, Mumbai, Maharashtra, India. Dr. Sadhna Joglekar is an ex-employee of Sun Pharmaceutical Industries Ltd, Mumbai, Maharashtra, India. Other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data that support the findings of this study are not openly available due to reasons of sensitivity, but are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was approved by the Royal Pune Independent Ethics Committee (RPIEC) located in Pune, India (EC approval number: RPIEC050322; dated 8 March 2022). The study was registered in the Clinical Trial Registry of India (CTRI number: CTRI\/2021\/06\/034238).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This retrospective study used anonymized data without additional prospective components for research purposes. Hence, obtaining informed consent from patients was not applicable for this study as it did not involve identifiable individuals. Accordingly, IEC\u2019s permission for an informed consent waiver was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not Applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not Applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: Y.G., S.M., S.J., R.S., S.G., S.P., and P.S.; data curation: R.S., S.G., S.P., and P.S.; methodology: Y.G., S.M., S.J., R.S., S.G., S.P., and P.S.; software: R.S., S.G., S.P., and P.S.; validation: Y.G., R.S., S.G., S.P., P.S., S.D., A.S., C.K., N.M., A.M., S.M., and S.J.; formal analysis: Y.G., S.D., C.K., N.M., S.M., and S.J.; investigation: R.S., S.G., S.P., and P.S.; resources: R.S., S.G., S.P., and P.S.; writing\u2014original draft preparation: Y.G., R.S., S.G., S.P., P.S., S.D., A.S., C.K., and N.M.; writing\u2014review and editing: Y.G., R.S., S.G., S.P., P.S., S.D., A.S., C.K., N.M., A.M., S.M., and S.J.; visualization: Y.G., R.S., S.G., S.P., P.S., S.D., A.S., C.K., N.M., A.M., S.M., and S.J.; supervision: Y.G., R.S., S.G., S.P., P.S., S.D., A.S., C.K., N.M., A.M., S.M., and S.J.; project administration: R.S., S.G., S.P., P.S., Y.G., C.K., N.M., S.M., and S.J.; funding acquisition: R.S., S.G., S.P., and P.S. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}